Drugs that contain Pitolisant Hydrochloride
1. Drug name - WAKIX
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8207197 | HARMONY | Monohydrochloride salt of 1-[3-[3-(4-chlorophenyl) propoxy] propyl] -piperidine |
Feb, 2029
(6 years from now) | |
| CN101155793B | HARMONY | 1-[3-[3-(4) Propoxy] Propyl Group]-Pyrazine And One Hydrochloride |
Feb, 2026
(3 years from now) | |
| CN101155793A | HARMONY | Monohydrochloride Of 1-[3-[3-(4-Chlorophenyl)Propoxy]Propyl]-Piperidine |
Feb, 2026
(3 years from now) | |
| IN247019B | HARMONY | A Process For The Production Of Crystalline Monohydrochloride Salt Of 1- [3-[3-(4-Chlorophenyl) Propoxy] Propyl] - Piperidine |
Feb, 2026
(3 years from now) | |
| IN200703493P4 | HARMONY | Monohydrochloride Salt Of 1- (Chlorophenyl) Propoxy Propyl - Piperidine |
Feb, 2026
(3 years from now) | |
| EP1690858A1 | HARMONY | Monohydrochloride Salt Of 1-[3-[3-(4-Chlorophenyl)Propoxy]Propyl]-Piperidine |
Feb, 2025
(2 years from now) | |
| EP1690858B1 | HARMONY | Monohydrochloride Salt Of 1-[3-[3-(4-Chlorophenyl)Propoxy]Propyl]-Piperidine |
Feb, 2025
(2 years from now) | |
| EP1846384B1 | HARMONY | Monohydrochloride Salt Of 1-[3-[3-(4-Chlorophenyl)Propoxy]Propyl]-Piperidine |
Feb, 2026
(3 years from now) | |
| EP1846384A1 | HARMONY | Monohydrochloride Salt Of 1-[3-[3-(4-Chlorophenyl)Propoxy]Propyl]-Piperidine |
Feb, 2026
(3 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8354430 | HARMONY | Monohydrochloride salt of 1-[3-[3-(4-chlorophenyl) propoxy]propyl]-piperidine |
Feb, 2026
(3 years from now) | |
| US8486947 | HARMONY | Treatment of Parkinson's disease, obstructive sleep apnea, dementia with Lewy bodies, vascular dementia with non-imidazole alkylamines histamine H3-receptor ligands |
Sep, 2029
(6 years from now) | |
Treatment: Method of treating excessive daytime sleepiness in patients with narcolepsy; method of treating cataplexy in patients with narcolepsy
Dosage: TABLET;ORAL
More Information on Dosage
| Strength | Dosage | Availability |
|---|---|---|
| EQ 4.45MG BASE | TABLET;ORAL | Prescription |
| EQ 17.8MG BASE | TABLET;ORAL | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.